Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of ...

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026

Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of ...

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of ...

EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December…

Kyverna announces positive data from trial of miv-cel in SPS - BioTuesdays

Kyverna Therapeutics (NASDAQ: KYTX) has announced positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel)—a fully human, autologous CD19-targeting CAR T-cell therapy with CD28 co-stimulation—in stiff person syndrome (SPS). KYSA-8 is a single-arm registrational, Phase 2 trial in which 26 patients with SPS, who’ve had an inadequate response with non-approved treatment options, received a single dos…

Kyverna Therapeutics (NASDAQ: KYTX) schedules Dec. 15 KYSA-8 topline SPS data call

Kyverna will host a live webcast and conference call on Dec. 15, 2025 at 8:00 am ET to review topline results from its registrational Phase 2 KYSA-8 trial in stiff person syndrome.